Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 10/2014

01-10-2014 | Letter to the Editor

The successful management of dabigatran-associated critical end-organ bleeding with recombinant factor VIIa

Authors: K. T. Htun, J. McFadyen, H. A. Tran

Published in: Annals of Hematology | Issue 10/2014

Login to get access

Excerpt

Dear Editor, …
Literature
1.
2.
Parameswaran R, Shapiro AD, Gill JC et al (2005) Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia 11:100–106PubMedCrossRef
3.
Warkentin TE, Margetts P, Connolly SJ et al (2012) Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood 1 119:2172–2174CrossRef
4.
Hoffman M, Volovyk Z, Monroe D (2013) Reversal of dabigatran effects by factor VIIa in a cell-based model of coagulation. ISTH 2013, Abstract in JTH, XXIV ISTH Congress
5.
Khoo TL, Weatherburn C, Kershaw G et al (2013) The use of FEIBA® in the correction of coagulation abnormalities induced by dabigatran. Int J Lab Hematol 35:222–224PubMedCrossRef
6.
Hapgood G, Butler J, Malan E et al (2013) The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples. Thromb Haemost 110:308–315PubMedCrossRef
7.
Eerenberg ES, Kamphuisen PW, Sijpkens MK et al (2011) Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 124:1573–1579PubMedCrossRef
8.
Makris M, Van Veen JJ, Tait CR et al (2013) Guideline on the management of bleeding in patients on antithrombotic agents. Br J Haematol 160:35–46PubMedCrossRef
Metadata
Title
The successful management of dabigatran-associated critical end-organ bleeding with recombinant factor VIIa
Authors
K. T. Htun
J. McFadyen
H. A. Tran
Publication date
01-10-2014
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 10/2014
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-014-2039-7

Other articles of this Issue 10/2014

Annals of Hematology 10/2014 Go to the issue

Original Article

High prognostic value of minimal residual disease detected by flow-cytometry-enhanced fluorescence in situ hybridization in core-binding factor acute myeloid leukemia (CBF-AML)

Letter to the Editor

Use of eltrombopag for the treatment of thrombocytopenia in hypoplastic myelodysplastic syndrome

Original Article

Health-related quality of life and persistent symptoms in relation to (R-)CHOP14, (R-)CHOP21, and other therapies among patients with diffuse large B-cell lymphoma: results of the population-based PHAROS-registry

Letter to the Editor

Independent growth of diffuse large B cell lymphoma and angioimmunoblastic T cell lymphoma originating from composite lymphoma

Letter to the Editor

Thromboelastometry changes in myeloproliferative neoplasms—surrogate for a procoagulant haemostatic imbalance or a consequence of technical reasons?

Letter to the Editor

Pneumatosis intestinalis and imatinib mesylate
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits